Reduced mitochondrial transcription sensitizes acute myeloid leukemia cells to BCL-2 inhibition
Preprint
- 5 June 2024
- preprint
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Abstract
Overcoming drug-resistance and the subsequent relapse that often occurs with monotherapy is crucial in the treatment of acute myeloid leukemia. We here demonstrate that therapy-resistant leukemia initiating cells can be targeted using a novel inhibitor of mitochondrial transcription (IMT). The compound inhibits mitochondrial RNA polymerase activity and sensitizes the resistant population to the induction of apoptosis. In vitro studies on acute myeloid leukemia cells demonstrate that IMT prevents cell proliferation, and together with a selective BCL-2 inhibitor, venetoclax, induces apoptosis and suppress oxidative phosphorylation (OXPHOS) synergistically. AML mouse models treated with IMT in combination with venetoclax show prolonged survival in venetoclax-resistant models. Our findings suggest that certain therapy-resistant leukemia cell populations display a unique dependency on mitochondrial transcription and can be targeted with IMT.Keywords
All Related Versions
This publication has 30 references indexed in Scilit:
- Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and BeyondTargeted Oncology, 2020
- Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesCancer Cell, 2019
- Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid LeukemiaCancer Cell, 2019
- Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem CellsCancer Cell, 2018
- Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic EfficacyCancer Cell, 2017
- Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemiaLeukemia Research, 2017
- Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer TreatmentCell Metabolism, 2017
- Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid LeukemiaCancer Cell, 2015
- Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid LeukemiaCancer Cell, 2011
- Leukemia stem cellsAnnals of Hematology, 2010